PARIS/BOSTON (Reuters) - Biotech company Genzyme Inc rejected an $18.5 billion buyout offer from French drugmaker Sanofi-Aventis SA on Monday, setting the stage for a protracted and potentially ...
Pressure mounted on Genzyme as its shares rose 6 percent in Frankfurt a day after French drugmaker Sanofi made public its month-old proposal to buy the U.S. biotech group for $18.5 billion (11.8 ...
About 18,000 gel-filled syringes sold by the Cambridge biotech Sanofi Genzyme to treat arthritis of the knee should not be used because that batch was linked to a surge in side effects, the company ...
February 14, 2007 - Genzyme Corporation (Nasdaq: GENZ) today announced fourth-quarter and full-year financial results for 2006. The company also offered a confident outlook for the coming year, during ...
On April 5, 2022, MediciNova, Inc. (NASDAQ:MNOV) filed a Form 8-K stating that Genzyme Corp., a subsidiary of Sanofi, filed an amended complaint against Novartis Gene Therapies, Inc., Novartis ...
This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in ...
Genzyme Corp. (Nasdaq: GENZ) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced the finalization of the license and collaboration agreement for mipomersen. The collaboration provides ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genzyme Corporation (NASDAQ: GENZ) announced today that the terms for the consent decree regarding the Allston manufacturing plant have been finalized. These terms ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results